ID: ALA3526982

Max Phase: Preclinical

Molecular Formula: C15H22N6O11S

Molecular Weight: 494.44

Molecule Type: Small molecule

Representations

Canonical SMILES:  N[C@@H](CCC(=O)O)C(=O)N[C@@H](CSCC(=O)N1CC([N+](=O)[O-])([N+](=O)[O-])C1)C(=O)NCC(=O)O

Standard InChI:  InChI=1S/C15H22N6O11S/c16-8(1-2-11(23)24)13(27)18-9(14(28)17-3-12(25)26)4-33-5-10(22)19-6-15(7-19,20(29)30)21(31)32/h8-9H,1-7,16H2,(H,17,28)(H,18,27)(H,23,24)(H,25,26)/t8-,9-/m0/s1

Standard InChI Key:  BDWLLPFUKGHHEZ-IUCAKERBSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 494.44

Molecular Weight (Monoisotopic): 494.1067

AlogP: -3.31

#Rotatable Bonds: 14

Polar Surface Area: 265.41

Molecular Species: ACID

HBA: 11

HBD: 5

#RO5 Violations: 1

HBA (Lipinski): 17

HBD (Lipinski): 6

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 3.45

CX Basic pKa: 8.15

CX LogP: -5.88

CX LogD: -8.79

Aromatic Rings: 0

Heavy Atoms: 33

QED Weighted: 0.09

Np Likeness Score: -0.13

References

1. Scicinski J, Oronsky B, Taylor M, Luo G, Musick T, Marini J, Adams CM, Fitch WL..  (2012)  Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.,  40  (9): [PMID:22699395] [10.1124/dmd.112.046755]

Source

Source(1):

• Scientific Literature